Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Vétoquinol SA
  6. Summary
    VETO   FR0004186856

VÉTOQUINOL SA

(VETO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/10/2021 09/13/2021 09/14/2021 09/15/2021 09/16/2021 Date
132.4(c) 132.8(c) 130.8(c) 125.4(c) 133.8(c) Last
1 283 1 037 1 300 3 577 2 834 Volume
-3.22% +0.30% -1.51% -4.13% +6.70% Change
More quotes
Estimated financial data (e)
Sales 2021 511 M 602 M 602 M
Net income 2021 54,6 M 64,3 M 64,3 M
Net cash position 2021 27,7 M 32,6 M 32,6 M
P/E ratio 2021 28,4x
Yield 2021 0,60%
Sales 2022 527 M 620 M 620 M
Net income 2022 54,4 M 64,0 M 64,0 M
Net cash position 2022 77,5 M 91,2 M 91,2 M
P/E ratio 2022 29,4x
Yield 2022 0,46%
Capitalization 1 582 M 1 862 M 1 862 M
EV / Sales 2021 3,04x
EV / Sales 2022 2,86x
Nbr of Employees 2 525
Free-Float 32,6%
More Financials
Company
Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine,... 
More about the company
Ratings of Vétoquinol SA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about VÉTOQUINOL SA
09/13VETOQUINOL : Meeting highlights from the Committee for Medicinal Products for Ve..
AQ
09/13VETOQUINOL : welcomes the Positive Opinion from the European Committee for Medic..
PU
07/29Vetoquinol Announces Earnings Results for the First Half of 2021
CI
06/04VÉTOQUINOL SA : Ex-dividend day for final dividend
FA
06/01VETOQUINOL : Innovation - New light therapy supports skin recovery in pets
PU
05/29VETOQUINOL : Descriptif du programme de rachat d'actions propres soumis à l'asse..
PU
05/04VETOQUINOL : AVIS DE REUNION VALANT AVIS DE CONVOCATION (french)
PU
04/30VÉTOQUINOL SA : Monthly statement on outstanding equity shares and voting rights
CO
04/16GLOBAL MARKETS LIVE : Daimler, GSK, Mattel
04/15Q1 2021 SALES :
PU
04/15Vetoquinol SA Reports Sales Results for the First Quarter of 2021
CI
04/15VÉTOQUINOL SA : 1st quarter earnings
CO
04/07Vetoquinol SA Proposes Dividend
CI
04/01VÉTOQUINOL SA : Annual results
CO
04/01Vetoquinol SA Reports Financial Results for 2020
CI
More news
News in other languages on VÉTOQUINOL SA
09/16VIRBAC : le titre grimpe après un relèvement de prévisions
09/15VETOQUINOL : Le parasiticide vétérinaire Felpreva® (tigolaner / émodepside / pra..
09/13VETOQUINOL : avis positif du CVMP pour un anti-parasitaire
08/10LES MARCHÉS EN HAUSSOLIDATION : 10 Août 2021
07/30EN DIRECT DES MARCHES : Iliad, L'Oréal, Saint-Gobain, Renault, BNP Paribas, Schn..
More news
Chart VÉTOQUINOL SA
Duration : Period :
Vétoquinol SA Technical Analysis Chart | VETO | FR0004186856 | MarketScreener
Technical analysis trends VÉTOQUINOL SA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 133,80 €
Average target price 125,83 €
Spread / Average Target -5,95%
EPS Revisions
Managers and Directors
Matthieu Frechin Chief Executive Officer & Non-Independent Director
Régis Vimal du Monteil Group Director-Finance & Legal Affairs
Étienne Frechin Chairman
Hans Hollegien Group Director-Marketing & Medical
Jean Deleforge Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
VÉTOQUINOL SA60.05%1 862
ZOETIS INC.22.52%96 102
ELANCO ANIMAL HEALTH INCORPORATED5.87%15 359
DECHRA PHARMACEUTICALS PLC44.23%7 418
VIRBAC55.67%3 677
JINYU BIO-TECHNOLOGY CO., LTD.-26.04%2 676